KB-1135

RG6139-PD1-hIgG4-S228P

12145

Home » RG6139-PD1-hIgG4-S228P

Background of RG6139-PD1-hIgG4-S228P

RG-6139 (RO-7247669) is under development for the treatment of metastatic solid tumors including metastatic melanoma, triple-negative breast cancer (TNBC), advanced or metastatic renal cell carcinoma, non-small cell lung cancer, metastatic urothelial cancer, ureter cancer, bladder cancer, urethra cancer and esophageal squamous cell carcinoma. It is administered via intravenous route. The therapeutic candidate is a bi-specific monoclonal antibody which acts by targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3).

Specifications

Catalog Number	KB-1135
Antibody Name	RG6139-PD1-hIgG4-S228P
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P
Target	PD1
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.
A novel bispecific checkpoint inhibitor antibody to preferentially block PD-1 and LAG-3 on dysfunctional TILs whilst sparing Treg activation.